Member Info for Bothwell

As noted a few weeks ago, Seeing Machines is going to play a huge role in the rollout of driver monitoring systems that will find their way into all cars over the coming years. One of the big companies that we will continue to see Seeing Machines tech in specifically is the range of cars found under the GM umbrella.

All cars that use GM’s Super Cruise autonomous driving tech, I expect will also be paired with Seeing Machines driver monitoring systems. Last week we got word that the 2021 Cadillac Escalade (one of the most popular SUVs in the GM stable) would be rolling out with a Super Cruise and driver attention system using Seeing Machines’ e-DME software.

I continue to expect more of this kind of news and more car brands, makes and models using Seeing Machines tech as a standard safety systems as they progress towards autonomous driving.

As Reddit has got involved I will be able to sell out quicker than I thought. An interesting week ahead.

Correct Heimdal. We will be rewarded but it has been a long time coming.

This is now going to Boom next week.

Only way is up for the next 3/4 weeks. 1.5 before results is now a given.

£90K and £50K buys are the end of today must have known what is happening tonight.

Huge buy in Australia.

ASX has just opened up 25%. 8h 38 until we open. Huge day ahead tomorrow.

Tomorrow will be a good day as if you don’t get in then you are going to miss out on the rise from here until 3/4 weeks time.

Looks like I was right!

The price has been lowered today so their mates can get in. We should be on the move higher tomorrow and quickly.

MM’s are getting in. Good Money to be made here in next 4 weeks.

Managing Director, Dave Wall, commented: “Drilling has now commenced at Merlin-1, with results expected within the next 4 weeks. 10th March

Surprised we haven’t had an update.

We will get there Dougie. Next year.

I am waiting for the buyout Rooky! It is the only way out of this one for me. Directors and Management have held us back.

It would appear that an acceptable entry price level (being the list price for FortacinTM
to wholesalers or direct purchasers in the US not including prompt pay, or other
discounts, rebates or reductions in price) for the US market is more than US$144 per
12 dose can/unit, exceeding the Group’s expectation on price (which is approximately
4 times the current price for a 12 dose can in Europe and the United Kingdom, as well
as being approximately 1.5 times the expected and currently modelled price by
Wanbang Pharmaceutical Marketing and Distribution Co., Ltd., the Company’s commercial strategic partner for the People’s Republic of China, that it expects to receive in China
FortacinTM).
). Payers unprompted wholesale acquisition prices of FortacinTM were
US$144 to US$500 per month (US$144 to US$500 for a 12 dose unit/can of
• •
The Group has engaged the third-party marketing consultant to further its recent payer research by building out the US market landscape, price sensitivity and reimbursement expectations for both payer coverage and adding patients’ out-of-pocket expenses (or copay) sensitivity. Based on the marketing consultant’s findings, it will provide further recommendations on pricing, reimbursement and market access expectations. It is expected that the recommendations will be available to the Group by May 2021 and assist with our negotiations with potential US commercial strategic partners.
52.4% of lives (83% of plans) would cover FortacinTM with or without a rider at all price points.

Spread is tight which means we are ready for the next 3 weeks. 1p is in sight.

What’s going on here today? Large buys or sells?

Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, said: “Can AI design a novel molecule for a novel target that has no known inhibitors and has not been validated in a disease? And now we have successfully linked both biology and chemistry and nominated the preclinical candidate for a novel target, with the intention of taking it into human clinical trials, which is orders of magnitude more complex and more risky problem to solve.

Insilico
ISM001: Progress at a GlanceFibrosis Target ID, Compound Generation and Validation in <18 months. Source: Insilico Medicine
To my knowledge this is the first case where AI identified a novel target and designed a preclinical candidate for a very broad disease indication. It is a major milestone for us as our ultimate moonshot is to go after senescence and we need to have many enabling AI technologies that help us understand and manipulate human biology in other chronic diseases.”

Insilico
Potent target inhibition of ISM018_055. Source: Insilico Medicine
The company also announced the formation of a team of over 20 expert drug hunters and drug developers in Shanghai led by Dr Feng Ren, former senior VP of biology and chemistry at Medicilon, and former head of chemistry at GSK, who joined Insilico in February as chief science officer. This team will be responsible for taking the AI-discovered drugs into human clinical trials and creating a broad portfolio of preclinical assets.